HA
Haleos Labs Limited (HALEOSLABS)
₹1,600.00
Mkt cap
₹487 Cr
P/E ratio
37.60
P/B
2.21
Div yield
0.09%
ROE
8.44%
ROCE
9.94%
EPS (TTM)
₹42.55
Book value
₹725
52W range
1,091–1,774
Sector
Healthcare
Price history
Previous close
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates [1]
NSE HALEOSLABSBSE 540679
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−9.81% from high₹1,600
₹1,091+46.64% from low₹1,774
Current
₹1,600.00
Prev close
₹1,580.50
Day
+1.23%
Price performance
1D
+1.23%
1W
+0.60%
1M
−0.70%
3M
+9.86%
6M
−0.54%
1Y
+29.29%
YTD
+18.17%
Financials
Revenue, profit & margin
P/E ratio
37.6×
HALEOSLABS is 16% above the sector median of 32.5×
HALEOSLABS37.6×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.60 | 89.11 | 82.50 | 81.37 | 94.78 | 75.14 | 72.94 | 91.38 | |
| YoY Sales growth | -14.77% | -18.39% | +41.21% | +23.98% | +13.28% | +17.42% | -0.98% | -10.86% | +3.71% | +12.03% | -15.68% | -11.59% | +12.30% | |
| Expenses | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 | 83.06 | |
| Operating Profit | 7.93 | 9.30 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 | 8.32 | |
| OPM % | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.50% | 9.10% | |
| Other Income | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1.00 | 0.42 | 0.18 | 2.01 | 0.46 | 0.08 | |
| Interest | 2.81 | 2.34 | 2.84 | 2.40 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.90 | 2.15 | |
| Depreciation | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.80 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 | 4.25 | |
| Profit before tax | 1.66 | 3.81 | 7.10 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.90 | 3.44 | 2.00 | |
| Tax % | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% | 12.50% | |
| Net Profit | -0.44 | 4.12 | 6.47 | 7.10 | 3.30 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 | 1.76 | |
| EPS in Rs | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.90 | 1.46 | 8.77 | 10.78 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.10%Promoter
Promoters72.10%
FIIs0.00%
DIIs0.31%
Public27.58%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Haleos Labs Limited | ₹1,610.80 | 37.55 | 487 | 0.09% | 2 | −46.56% | 91 | +12.30% | 9.94% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports10
Concall transcripts1
Credit ratings6
Announcements5
Newspaper Publication (Financial Results) 12 Nov - Enclosed - Newspaper advertisement for Q2F27 (results)Board Meeting Outcome for Meeting Held On November 11, 2026 11 Nov - Board approved Q2 FY26 results and in-principle strategic alliance with HRV Global Life Sciences.Board Meeting Intimation for 99Th Board Meeting (11.11.2026) 7 Nov - Board meeting on November 11, 2026 to consider Q2 FY27 standalone and consolidated results; trading window closes till November 13.Temporary Withholding Of Dividend 31 Oct - Haleos Labs withholds FY26 dividend for shareholders with incomplete KYC or incorrect bank details.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 15 Oct






